Coeptis Therapeutics Ownership
| COEP Stock | USD 16.42 0.50 3.14% |
Shares in Circulation | First Issued 2004-09-30 | Previous Quarter 3.7 M | Current Value 4.7 M | Avarage Shares Outstanding 13.3 M | Quarterly Volatility 12.4 M |
Coeptis Stock Ownership Analysis
About 13.0% of the company shares are held by company insiders. The company recorded a loss per share of 6.87. Coeptis Therapeutics last dividend was issued on the 6th of August 2020. The entity had 1:20 split on the 31st of December 2024. Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania. Coeptis Therapeutics is traded on NASDAQ Exchange in the United States. For more info on Coeptis Therapeutics please contact the company at 724 934 6467 or go to https://coeptistx.com.Besides selling stocks to institutional investors, Coeptis Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Coeptis Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Coeptis Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Coeptis Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Coeptis Therapeutics Insider Trades History
About 13.0% of Coeptis Therapeutics are currently held by insiders. Unlike Coeptis Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Coeptis Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Coeptis Therapeutics' insider trades
Coeptis Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Coeptis Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Coeptis Therapeutics backward and forwards among themselves. Coeptis Therapeutics' institutional investor refers to the entity that pools money to purchase Coeptis Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Vanguard Group Inc | 2025-06-30 | 27.5 K | Geode Capital Management, Llc | 2025-06-30 | 20.3 K | Steward Partners Investment Advisory, Llc | 2025-06-30 | 1000 | Tower Research Capital Llc | 2025-06-30 | 268 | Ubs Group Ag | 2025-06-30 | 82.0 | Bank Of America Corp | 2025-06-30 | 25.0 | Barclays Plc | 2025-06-30 | 3.0 | Semmax Financial Advisors Inc. | 2025-06-30 | 0.0 | Advisor Group Holdings, Inc. | 2025-06-30 | 0.0 | Mint Tower Capital Management B.v. | 2025-03-31 | 0.0 |
Coeptis Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Coeptis Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Coeptis Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Coeptis Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Coeptis Therapeutics Outstanding Bonds
Coeptis Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Coeptis Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Coeptis bonds can be classified according to their maturity, which is the date when Coeptis Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Coeptis Therapeutics Corporate Filings
10Q | 14th of November 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 3rd of October 2025 Other Reports | ViewVerify | |
| 15th of August 2025 Other Reports | ViewVerify | |
| 7th of August 2025 Other Reports | ViewVerify |
Pair Trading with Coeptis Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Coeptis Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Coeptis Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Coeptis Stock
| 0.56 | 688578 | Shanghai Allist Phar | PairCorr |
| 0.54 | EQ | Equillium | PairCorr |
| 0.42 | PANACEABIO | Panacea Biotec | PairCorr |
| 0.39 | DRMA | Dermata Therapeutics | PairCorr |
| 0.37 | PYC | Physiomics Plc | PairCorr |
The ability to find closely correlated positions to Coeptis Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Coeptis Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Coeptis Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Coeptis Therapeutics to buy it.
The correlation of Coeptis Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Coeptis Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Coeptis Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Coeptis Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Coeptis Stock Analysis
When running Coeptis Therapeutics' price analysis, check to measure Coeptis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coeptis Therapeutics is operating at the current time. Most of Coeptis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Coeptis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coeptis Therapeutics' price. Additionally, you may evaluate how the addition of Coeptis Therapeutics to your portfolios can decrease your overall portfolio volatility.